Observational studyMedicine2016
Neurosarcoidosis in a Tertiary Referral Center: A Cross-Sectional Cohort Study.
Observational study in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Neurosarcoidosis - Epidemiological, Clinical, Diagnostic, and Therapeutic Aspects: A Systematic Review.CNS & neurological disorders drug targets · 2026Pooled it
- Cerebral vasculitis related to neurosarcoidosis: a case series and systematic literature review.Journal of neurology · 2025Pooled it
- Pooled it
- Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis.BMC neurology · 2016Pooled it
- Systemic Sarcoidosis With Neurosarcoidosis and Obstructive Hydrocephalus: A Radiologic-Pathologic Case Report.Journal of medical cases · 2026Article
- An update on hypophysitis.Nature reviews. Endocrinology · 2026Review
- Neurosarcoidosis mimicking multiple meningiomas: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Epidemiology, Clinical Features and Treatment of Neurosarcoidosis in Northern Spain.Biomedicines · 2025Article
- Panhypopituitarism in Neurosarcoidosis: Pituitary-Hypothalamic Involvement Successfully Managed With Rituximab.JCEM case reports · 2025Article
- Clinical and Laboratory Characteristics of Patients with Neurosarcoidosis.Noro psikiyatri arsivi · 2025Article
- Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort.Brain and behavior · 2024Observational
- Granuloma, vasculitis, and demyelination in sarcoid neuropathy.European journal of neurology · 2024Article
- Predictors of unfavourable outcome in adults with suspected central nervous system infections: a prospective cohort study.Scientific reports · 2023Article
- Tumefactive brain parenchymal neurosarcoidosis.Journal of neurology · 2023Article
- Rare Presentations of Sarcoidosis: A Case Series.Cureus · 2023Article
- Insights into neurosarcoidosis: an imaging perspective.Polish journal of radiology · 2023Review
- Pachymeningitis in Biopsy-Proven Sarcoidosis: Clinical Course, Radiographic Findings, Response to Treatment, and Long-term Outcomes.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Neurosarcoidosis of the Cauda Equina: Clinical Course, Radiographic and Electrodiagnostic Findings, Response to Treatment, and Outcomes.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Article
- Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: A mono-centric retrospective study and literature review.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 4 countries.
Funding
Abstract
The aim of this study was to evaluate clinical characteristics, diagnostic strategy, and treatment in patients with neurosarcoidosis in a tertiary referral centre.In a cross-sectional study, we included all patients with neurosarcoidosis treated at our tertiary referral center between September 2014 and April 2015.We identified 52 patients, among them 1 patient was categorized as having definite neurosarcoidosis, 37 probable neurosarcoidosis, and 14 possible neurosarcoidosis. Neurologic symptoms were the first manifestation of sarcoidosis in 37 patients (71%). Chronic aseptic meningitis was the most common presentation (19/52 patients [37%]), followed by cranial neuropathy (16/52 patients [31%]). Serum angiotensin-converting enzyme and lysozyme levels were elevated in 18 of 41 (44%) and 12 of 26 cases (46%). Pulmonary or lymph node sarcoidosis was identified by chest X-ray in 21 of 39 cases (54%) and by computed tomography of the chest in 25 of 31 cases (81%); Fluorodeoxyglucose-Positron emission tomography showed signs of sarcoidosis in 15 of 19 cases (79%). Thirty-one of the 46 cases receiving treatment (67%) improved, 13 cases (28%) stabilized, and 2 cases (4%) deteriorated. First-line treatment with corticosteroids resulted in satisfactory reduction of symptoms in 21 of 43 patients (49%). Seventeen patients (33%) needed second-line cytostatic treatment, and 10 patients (19%) were treated with tumor necrosis factor-α inhibitors.The majority of patients with neurosarcoidosis present with chronic meningitis without a history of systemic sarcoidosis. The diagnosis can be difficult to make because of the poor sensitivity of most diagnostic tests. Half of patients had a satisfactory reduction of symptoms on first-line therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.